Digital Health, Technology & InnovationArrowhead Starts Phase 1/2a Study of ARO-DIMER-PABusiness WireJanuary 27, 2026January 28, 2026 by Business WireJanuary 27, 2026January 28, 2026037 – ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule – In preclinical studies, ARO-DIMER-PA...
